Emerging studies suggest Retatrutide , a dual stimulator targeting both incretin and GIP , may provide a notable advancement for body treatment. Preliminary patient tests have shown impressive decreases in visceral fat , possibly exceeding current weight-loss treatments. Despite this, further study is required to fully assess its sustained effectiv